tVNS and Epilepsy: What the Evidence Actually Shows

Why This Article?

Approximately 50 million people worldwide live with epilepsy. Epilepsy is one of the most common neurological conditions, affecting roughly 1 in 100 people in the UK. For two-thirds of them, the right medication brings their seizures under control. But for the remaining third, roughly 30% of all people with epilepsy, the drugs simply don't work well enough. These individuals are classified as having drug-resistant epilepsy (DRE), defined by the International League Against Epilepsy as the failure of two or more adequately trialled anti-seizure medications.

That is a significant number of people for whom the standard approach falls short.

As someone who has worked with electrical stimulation for many years, I have watched neuromodulation technologies evolve from curiosities into clinically validated tools. Vagus nerve stimulation is one of the most compelling examples of this evolution. The vagus nerve carries dense afferent fibres from the body to the brainstem (nucleus tractus solitarius, NTS), which project to autonomic, limbic, and cortical areas. Through these connections, vagal input helps regulate autonomic tone, inflammation, arousal, and neuroplasticity. The surgically implanted stimulator version (VNS) has been FDA-approved for epilepsy since 1997. But not everyone with drug-resistant epilepsy is suitable for surgery, willing to undergo it, or able to access it.

This is where transcutaneous vagus nerve stimulation (tVNS) comes in: a non-invasive approach that delivers vagal stimulation through the skin of the ear, avoiding the need for surgery altogether. Anatomical Concepts distributes the tVNS® system in the UK, and this article provides clinicians with a thorough overview of the evidence for tVNS in epilepsy. There are numerous wellness devices for vagus nerve stimulation, but only the tVNS® system is a regulated medical device and can substantiate medical claims.

What does the research actually show? Where is the evidence strong, and where are the gaps? What does this mean in practical clinical terms?

Let me walk you through it.

The Clinical Challenge: Drug-Resistant Epilepsy

Before looking at the solution, it's worth understanding the scale of the problem.

Drug-resistant epilepsy significantly impairs quality of life. It increases the risk of sudden unexpected death in epilepsy (SUDEP). It creates a substantial social, psychological, and economic burden for patients and their families. The fact is that for many people living with DRE, the management challenge is not simply medical; it touches every aspect of daily life.

For eligible patients, resective neurosurgery offers the highest chance of seizure freedom, but it requires an identifiable, safely removable epileptogenic focus. Where surgery is not viable, neuromodulation becomes the principal alternative. This includes deep brain stimulation (DBS), responsive neurostimulation (RNS), and vagus nerve stimulation (VNS). Of these, VNS has the longest track record, with FDA approval initially covering adults and children aged 12 years with partial-onset seizures, later extended to children aged 4 years.

The development of transcutaneous delivery systems for VNS represents something genuinely important: it removes the surgical barrier entirely, making vagal neuromodulation accessible earlier and to a broader population.

Why the Ear? The Anatomy Behind tVNS

If you're going to stimulate the vagus nerve through the skin, you need a reliable access point. The auricular branch of the vagus nerve (ABVN), sometimes called Arnold's nerve, provides exactly that.

The ABVN arises from the superior ganglion of the vagus nerve within the jugular foramen, traverses a small bony canal in the petrous bone, and emerges from the tympanomastoid fissure to innervate portions of the external ear. The cutaneous vagal afferent territory within the auricle includes the cymba conchae, concha, part of the tragus, and antihelix.

The critical issue is where on the ear you stimulate. An fMRI study comparing four auricular sites (inner tragus, posterior canal, cymba conchae, and earlobe sham) established that cymba conchae stimulation produces the greatest and most specific activation of the nucleus tractus solitarius (NTS) and locus coeruleus in the brainstem. The cymba conchae has 100% vagal innervation, compared with approximately 45% at the tragus. This anatomical precision matters enormously: stimulation at the wrong site simply does not activate the brainstem pathways that drive the therapeutic effect.

In other words, not all ear-based VNS is equal. The site of stimulation is a critical variable.

Nerve Fibre Composition: A Detail That Matters

The cervical vagus nerve is composed of approximately 80% afferent (sensory) and 20% efferent (motor) fibres, with roughly 65 to 80% being unmyelinated C fibres and the remainder myelinated A and B fibres. The therapeutic effects in epilepsy are attributed primarily to the recruitment of the thicker, myelinated A and B fibre populations, rather than C fibres. Research confirms this: pharmacological destruction of peripheral C fibres does not abolish VNS-induced seizure suppression.

The ABVN contains predominantly Aδ and Aβ class myelinated axons, with very few motor fibres. However, the ABVN contains approximately six times fewer Aβ fibres than the cervical trunk. This may partly explain why tVNS via the auricular route tends to achieve somewhat lower seizure-suppression magnitudes than implanted VNS, and why there is variability in individual responses. It's an honest observation, and one that's important for setting realistic expectations.

How Does tVNS Suppress Seizures?

The mechanism by which VNS suppresses seizures is not fully understood, but it is increasingly well characterised. Let me outline the key pathways.

The Noradrenergic Pathway: The Best-Supported Mechanism

Vagal afferents project to the nucleus tractus solitarius (NTS) in the medulla, which sends strong ascending projections to the locus coeruleus (LC). The LC is the brain's primary source of norepinephrine (NE) and projects diffusely to the cortex and hippocampus. VNS increases LC firing and elevates extracellular NE concentrations in both regions. The evidence is direct: LC lesions abolish the anti-seizure efficacy of VNS in animal models.

In human tVNS studies, LC activation has been confirmed through proxy biomarkers. Transient pupil dilation and attenuation of occipital alpha oscillations, both established signatures of LC-NE activity, are reliably induced by brief tVNS bursts. Pharmacological studies indicate that the antiepileptic effect is mediated specifically by α2-adrenoreceptor activation downstream of NE release.

Serotonergic and GABAergic Contributions

VNS also modulates the serotonergic system via NTS projections to the raphe nuclei and increases GABA release in cortical and hippocampal circuits. GABAergic effects of tVNS have been directly demonstrated in human EEG studies, including evidence of immediate changes in GABA transmission after single sessions. The combined noradrenergic, serotonergic, and GABAergic modulation plausibly explains both the antiepileptic and mood-stabilising properties of VNS and tVNS.

Anti-Inflammatory Effects

The cholinergic anti-inflammatory pathway (activation of the efferent vagus → α7-nicotinic acetylcholine receptors on macrophages → suppression of TNF-α and other pro-inflammatory cytokines) represents a distinct mechanism potentially relevant to epilepsies with a neuroinflammatory basis. This pathway is better established for implanted VNS but is thought to be engaged by taVNS to some degree.

Effects on Epileptic Brain Networks

At the network level, taVNS has been shown, via EEG-derived functional connectivity analyses, to induce measurable and persistent modifications in large-scale epileptic brain networks. In most subjects studied during long EEG recording sessions, short-term taVNS enhanced network resilience, stability, and robustness (properties that are inversely correlated with seizure propensity) without adversely affecting cognition or mood. These modifications differed systematically between focal and generalised epilepsy types, suggesting taVNS engages somewhat distinct network topologies depending on the underlying disorder.

KEY POINT: The mechanisms of tVNS in epilepsy are multi-layered. The noradrenergic pathway through the locus coeruleus is the best-supported mechanism, but serotonergic, GABAergic, anti-inflammatory, and network-level effects all appear to contribute. This mechanistic breadth may explain both the therapeutic versatility of vagal stimulation and its effects on comorbid conditions like depression and anxiety.

Stimulation Delivery: Devices and Parameters

The Devices

Two main transcutaneous routes are used in practice:

Transcutaneous auricular VNS (taVNS) applies electrodes to the external ear to target the ABVN. This is by far the most studied approach for epilepsy. The most clinically validated platform is the tVNS® system (tVNS Technologies GmbH, Germany), CE-marked since 2010 and now holding Class IIa certification under EU-MDR 2017/745. It is the device distributed by Anatomical Concepts in the UK.

Transcutaneous cervical VNS (tcVNS) applies electrodes over the sternocleidomastoid to stimulate the cervical vagus trunk. The gammaCore® (electroCore) is FDA-cleared for migraine and cluster headache but not for epilepsy.

Stimulation Parameters

Clinical trials have converged on a relatively consistent parameter set, though optimisation remains incomplete:

Parameter	Typical Clinical Range	Most-Used in Epilepsy Trials
Frequency	1 to 25 Hz	10 to 25 Hz
Pulse width	200 to 500 µs	200 to 250 µs
Intensity	Sub-pain threshold	Maximum tolerated (0.5 to 6 mA)
Duty cycle	30s on / 30s off	30s on / 30s off
Daily duration	20 min to 4 h	2 to 4 h/day

The convention is to stimulate the left ear, following the practice established for implanted VNS (due to the asymmetric cardiac innervation of right vs. left vagus). However, the cardiac risk from bilateral ABVN stimulation is anatomically much lower than for cervical VNS, and bilateral paediatric use has been reported as safe.

An important parameter finding: 25 Hz appears to outperform 1 Hz stimulation in most datasets. This distinction matters because several trials have used 1 Hz as an "active control," but evidence increasingly suggests that 1 Hz stimulation may itself exert some anti-seizure activity, which complicates interpretation.

The Clinical Evidence: What Do the Trials Show?

This is the section that matters most for clinicians making decisions. Let me present the evidence systematically, from the early pilot studies through to the meta-analyses.

Early Pilot Studies

The first clinical proof-of-concept came from Stefan et al. (2012), who applied taVNS (left tragus, 10 Hz, 0.3 ms, three sessions of 1 hour daily, for 9 months) to 10 adults with DRE. Of the 7 who completed the study, 5 showed reduced seizure frequency.

He et al. (2013) extended this to a paediatric cohort of 14 children, using bilateral concha stimulation at 20 Hz for three sessions of 30 minutes daily for 6 months, reporting a mean 54% reduction in seizure frequency. This was the first evidence that tVNS was safe and potentially efficacious in children.

Liu et al. (2018) reported an average seizure reduction of 64.4% in 16 out of 17 patients after 6 months of tVNS (cymba conchae, 10 Hz, three sessions of 20 minutes daily), though this small uncontrolled study must be interpreted with caution.

These early studies were small and uncontrolled, but they provided sufficient signals to justify larger, properly designed trials.

The cMPsE02 Trial (Bauer et al., 2016)

The cMPsE02 trial remains a landmark: a randomised, double-blind controlled study specifically designed to test taVNS superiority over active control in DRE. Seventy-six patients were randomised to 25 Hz (n=39) vs. 1 Hz active control (n=37) stimulation at the cymba conchae using the NEMOS device, 4 hours daily for 20 weeks.

The primary endpoint on an intention-to-treat basis did not reach statistical significance. Mean seizure reduction was 23.4% in the 25 Hz group vs. -2.9% in the 1 Hz group (p=0.146). However, the completers analysis (n=26) showed a significant 34.2% seizure reduction in the 25 Hz group (p=0.034).

Why didn't the primary endpoint reach significance? Three likely factors: the 1 Hz "control" stimulation may itself have had some anti-epileptic effect (making it not truly inert), patient selection was heterogeneous, and the study was probably underpowered. The completers analysis nonetheless provided the first randomised, double-blind evidence that high-frequency taVNS has a genuine anti-seizure effect.

KEY POINT: The cMPsE02 trial illustrates a recurring challenge in tVNS research: designing a true sham. If 1 Hz stimulation is itself biologically active, then comparing 25 Hz against 1 Hz underestimates the true treatment effect. This is an important interpretive point for clinicians reviewing the literature.

Yang et al. (2023): The Largest RCT to Date

This 150-patient multicentre double-blind RCT is the strongest single piece of evidence for taVNS in epilepsy. Adults with DRE were randomised 2:1 to active taVNS (n=100; 25 Hz, 250 µs, 30s on/30s off, 2 hours daily at maximum tolerated intensity, cymba conchae) or sham control (n=50; 1 Hz at minimum perceptible intensity) for 20 weeks, across four major Chinese epilepsy centres.

The results:

• Responder rate (≥50% seizure reduction) at 20 weeks: 44.74% active vs. 16.67% control (p < 0.05)
• Mean seizure reduction at 20 weeks: 30.75% (active) vs. 15.66% (control) (p = 0.038)
• The anti-seizure effect increased with treatment duration, becoming significant only at 20 weeks
• No severe adverse events in either group

Two observations stand out. First, the responder rate of nearly 45% is clinically meaningful for a non-invasive, non-surgical intervention in drug-resistant epilepsy. Second, the benefit was cumulative, emerging clearly only at 20 weeks. This is consistent with the known time course of VNS neuromodulation and has practical implications: patients and clinicians need to commit to at least 20 weeks before judging response.

The trial did not show significant improvements in quality of life (QOLIE-31), anxiety, depression, or cognition at 20 weeks, though the study duration may have been insufficient to capture these secondary benefits.

Beijing Tiantan Real-World Study (2024)

Moving from controlled trials to real-world practice, a prospective study at Beijing Tiantan Hospital enrolled 99 DRE patients undergoing taVNS with 1 to 2 years of follow-up. Of 65 patients with successful follow-up:

• Overall efficacy rate (≥50% seizure reduction): 61.54%
• 15 patients (23.1%) achieved more than 90% seizure reduction
• 8 patients (12.3%) achieved 75 to 90% reduction
• 17 patients (26.2%) achieved 50 to 75% reduction
• Mild adverse events (ear tingling, tinnitus) in 10 patients; no severe events
• Efficacy was independent of measured clinical variables, suggesting broad applicability

The higher efficacy rate in this real-world study compared with the RCTs likely reflects longer follow-up and possibly greater patient motivation in a clinical setting. It provides encouraging real-world validation of the controlled trial findings.

What the Meta-Analyses Tell Us

Two independent meta-analyses of RCT data have now been published.

The first (2025, 4 RCTs, 417 subjects) found significant reductions in seizure frequency at 8, 12, 16, and 52 weeks, with a favourable safety profile. The second (2026, 4 RCTs, 359 patients) confirmed a significant decrease in seizure frequency favouring tVNS (p=0.008).

However, neither meta-analysis found a statistically significant difference in responder rate (≥50% seizure reduction) between active and control groups in pooled analysis. This apparent contradiction, significant reduction in seizure frequency but non-significant difference in responder rate, is partly explained by the fact that 1 Hz "control" stimulation may itself exert mild anti-seizure activity, and partly by heterogeneity across studies.

The Yang 2023 trial, with the most robust sham design, did show a significant responder rate difference (44.74% vs. 16.67%). This suggests the true treatment effect may be larger than pooled meta-analytic estimates indicate.

KEY POINT: The evidence base for tVNS in drug-resistant epilepsy now includes two substantial RCTs, multiple pilot studies, real-world prospective data, and two meta-analyses. The consistent finding is a statistically significant reduction in seizure frequency with a favourable safety profile. Responder rates of 45 to 62% have been reported in the strongest studies. The evidence is not yet at the level of implanted VNS, but it is substantial and growing.

Efficacy Across Epilepsy Subtypes

Focal vs. Generalised Epilepsy

Most taVNS epilepsy data comes from mixed DRE populations with predominantly focal-onset seizures. Network analysis studies indicate that taVNS modifies functional brain networks differently depending on epilepsy type, but it is not yet established whether efficacy differs significantly between focal and generalised epilepsy for taVNS specifically. For implanted VNS, broadly similar response rates are seen across seizure types.

Lennox-Gastaut Syndrome

Evidence-based guidelines for implanted VNS confirm that it is possibly effective for LGS-associated seizures in children, with more than 50% seizure reduction in approximately 55% of cases. By extension, taVNS may offer benefit in LGS, but specific RCT data for taVNS in this population are not yet available.

Temporal Lobe Epilepsy and Cognition

A randomised double-blind study of 28 patients with refractory temporal lobe epilepsy showed that 20 weeks of taVNS significantly shortened reaction time in working memory tasks (p=0.010) and modulated frontal midline theta oscillations in the active group. This is a promising signal given the high cognitive comorbidity burden in DRE.

Paediatric Epilepsy

The tVNS® E device is approved under EU-MDR for use in children from age 3 years for epilepsy. The He 2013 paediatric pilot demonstrated safety and 54% seizure reduction with bilateral auricular use. For implanted VNS, a systematic review of 101 paediatric studies found 56.4% of children achieving ≥50% seizure reduction and 11.6% achieving seizure freedom. The efficacy of taVNS in children has not been tested in a dedicated paediatric RCT, but current pilot data support exploring this further, especially given the avoidance of paediatric surgical risks.

How Does tVNS Compare with Implanted VNS?

This is a question clinicians rightly ask. The honest answer is that no head-to-head RCT comparing the two approaches exists, so we are drawing comparisons across studies with different designs and populations. With that caveat, here is what we can say:

Feature	Implanted VNS	tVNS
Delivery	Cervical electrode + pulse generator	Auricular skin electrodes
Surgery required	Yes (general anaesthetic)	No
Regulatory status (epilepsy)	FDA + CE approved	CE approved (Class IIa EU-MDR); not FDA approved
Responder rate (≥50% reduction)	~45 to 65% at 6 to 12 months	~27 to 62% depending on study
Seizure freedom rate	~5 to 10%	Not well established
Long-term efficacy	Increases over years	Limited long-term data
Stimulation mode	Continuous + on-demand; AutoStim	User-administered, 2 to 4 h/day
Side effects (stimulation)	Voice alteration, hoarseness, cough in 10 to 40%	Mild: ear tingling, local discomfort
Surgical complications	Infection, bradycardia, haematoma, vocal cord paresis	None
Cost	~£20,000 to 50,000 (device + surgery + follow-up)	Hundreds to low thousands of pounds
Reversibility	Requires surgery to remove	Fully reversible

The closed-loop AutoStim mode in implanted VNS (responding to ictal tachycardia, present in approximately 80% of seizures) has substantially improved outcomes; one series reports 69.3% of DRE patients achieving ≥50% seizure reduction with AutoStim active. This remains a significant advantage of implanted VNS over current open-loop taVNS systems. Closed-loop taVNS prototypes are under development, but they are not yet clinically available.

KEY POINT: tVNS is not a replacement for implanted VNS. It is an alternative, particularly suited to patients who decline surgery, are not surgical candidates, or who want to try a non-invasive approach before committing to implantation. The responder rates are somewhat lower than the best implanted VNS results, but the absence of surgical risk and the substantially lower cost make tVNS a clinically rational first step in many cases.

Safety Profile

One of the most compelling aspects of tVNS is its safety record. Across all published trials and real-world studies, no severe device-related adverse events have been reported.

Common, mild and transient (reported in up to 20% of patients):

• Local skin effects: erythema, tingling, itching at electrode site
• Headache, sleep disturbance
• Ear tingling, tinnitus

Uncommon:

• Transient sinus bradycardia (1 case in the 150-patient RCT; self-resolving)
• Nausea, dizziness, hoarseness (much less frequent than with implanted VNS)

By comparison, implanted VNS carries significant surgical risks including infection (3 to 7%), vocal cord paresis, bradycardia during implantation, and device fracture. The cumulative stimulation side effects of hoarseness and dyspnoea affect up to 40% of patients at therapeutic intensities. The avoidance of these complications represents a major practical advantage.

Cardiac monitoring is prudent at initiation, particularly in patients with pre-existing cardiac disease. But in my experience with neuromodulation devices, the safety profile of tVNS is genuinely reassuring.

Regulatory and Access Context

The tVNS® E device (tVNS Technologies GmbH, Germany) received CE marking for epilepsy and depression in 2010 and now holds Class IIa certification under EU-MDR 2017/745, verified by TÜV SÜD. The EU-MDR approval covers epilepsy, depression, anxiety, cognitive impairment, migraine, IBS/IBD, tinnitus, Parkinson's disease, Prader-Willi syndrome, and atrial fibrillation, among others.

The device is not FDA-approved for epilepsy in the United States, where the gammaCore® holds FDA clearance only for migraine and cluster headache.

For UK practice, NICE evidence reviews for VNS in epilepsy have addressed implanted VNS but have not yet specifically evaluated taVNS in a formal health technology assessment context. Given the CE marking, taVNS can be used in UK clinical practice, though formal NICE guidance specific to taVNS for epilepsy is currently lacking. This is a gap that deserves attention as the evidence base continues to grow.

Predicting Response: Who Benefits Most?

Response to VNS, and by extension tVNS, is heterogeneous. Not everyone responds equally, and being honest about this matters. Several predictive factors have been identified:

• Lower baseline seizure frequency is consistently associated with better response. Patients with 30 or fewer seizures per month show faster and more robust improvements.
• Age at seizure onset of 6 years or older predicts better outcomes with implanted VNS.
• Focal epilepsy with identifiable networks may respond better than multifocal or encephalopathic patterns.
• EEG reactivity (power spectral differences in response to external stimuli) predicts responders vs. non-responders with high accuracy. This biomarker approach is translatable to taVNS.
• P300 event-related potential amplitude, a non-invasive biomarker of LC-NE activation, correlates with VNS efficacy and may be used to pre-screen candidates.

These predictive markers are not yet routinely applied in clinical taVNS practice, but they represent an important direction for personalising patient selection. A lot depends on individual circumstances, and research suggests it may be possible to identify likely responders before committing to long-term therapy.

Beyond Seizures: Comorbidity Benefits

Beyond seizure frequency reduction, tVNS exerts broader neuromodulatory effects that are particularly relevant to the DRE population. This is worth noting because drug-resistant epilepsy rarely exists in isolation.

• Mood: The tVNS device is EU-MDR approved for anxiety and depression. Implanted VNS carries a specific antidepressant indication, attributed to serotonergic and noradrenergic effects. taVNS studies in epilepsy have not yet demonstrated significant mood improvement at 20 weeks, but longer-duration studies in depression show consistent benefit.
• Working memory: 20 weeks of taVNS significantly improved working memory performance and modulated frontal theta oscillations in temporal lobe epilepsy patients.
• Social cognition: tVNS has been shown to boost cooperative behaviour in epilepsy patients, an effect mediated via dopaminergic reward circuits engaged through vagal signalling.
• Drop attacks and clusters: For implanted VNS, more than 70% of patients with drop attacks show improvement, with more than 80% reporting decreased seizure cluster frequency or duration.

The dual antidepressant and antiepileptic indication of tVNS is clinically attractive for this population, where depression and anxiety are common comorbidities.

What We Don't Yet Know

Here are the key unanswered questions:

Closed-loop delivery: The most significant methodological frontier. Current taVNS is open-loop, delivering fixed parameters on a schedule. Closed-loop approaches that trigger stimulation in response to pre-seizure EEG signatures, or synchronise with the respiratory cycle, may enhance efficacy. These prototypes are under development but not yet clinically available.

Long-term outcomes: Most RCT data extend only to 20 weeks. The real-world Beijing Tiantan data (1 to 2 years) suggest sustained benefit, but we need larger, longer-duration controlled studies.

Head-to-head comparison: No RCT has directly compared tVNS with implanted VNS in epilepsy. Such a trial is needed to quantify the trade-off between the non-invasive approach's tolerability and the implanted system's more intensive stimulation capability.

Optimal parameters: The trend toward 25 Hz, cymba conchae, and multi-hour daily treatment is empirically supported, but a systematic dose-response study has not been conducted.

Status epilepticus: Implanted VNS has shown benefit in new-onset refractory status epilepticus (NORSE) in case reports and small series. Whether taVNS could play a role is an important unanswered question. A UK-wide NORSE-UK network study is planned to evaluate VNS for NORSE.

Practical Guidance for Clinicians

For UK clinicians considering taVNS in epilepsy management, the following practical points are relevant.

Candidate Selection

• Adults (and children ≥3 years under EU-MDR) with confirmed DRE having failed two or more ASMs
• Not suitable for or unwilling to undergo resective surgery
• Absence of cardiac pacemakers or implanted metallic devices near the ear
• Exclusion of severe cardiac arrhythmia, active peptic ulcer

Treatment Initiation

• Establish a baseline seizure diary (minimum 8 weeks recommended)
• Titrate intensity to maximum tolerated (just below pain threshold), typically 0.5 to 6 mA
• 25 Hz, 200 to 250 µs pulse width, 30s on/30s off, 2 to 4 hours daily (can be divided into sessions)
• Maintain stable ASM regimen during the initial 20-week assessment period
• Assess response at 8, 12, and 20 weeks using a standardised seizure diary

What to Tell Your Patients

• The anti-seizure benefit typically becomes apparent from 12 weeks, with maximum effect at 20 weeks or beyond. This is not a quick fix.
• Based on the available evidence, there is approximately a 45-60% chance of achieving a 50% or greater reduction in seizures.
• Mild local side effects (tingling, redness at the electrode site) are expected and generally well tolerated.
• The device is used as an adjunct to anti-seizure medications, not a replacement.
• Brief baseline cardiac monitoring is prudent at initiation.

Comorbidity Considerations

Depression and anxiety are common in DRE. The dual antidepressant and antiepileptic indication of tVNS is clinically attractive for this population. Cognitive and quality-of-life benefits may take longer than seizure benefits to emerge, so patience is warranted.

Conclusion

The most honest summary is this: transcutaneous vagus nerve stimulation is a clinically validated, non-invasive approach to the adjunctive management of drug-resistant epilepsy. The neurophysiological rationale is well grounded in the NTS-locus coeruleus-norepinephrine pathway, supported by direct human biomarker studies. The clinical evidence, anchored by two substantial RCTs and confirmed by meta-analyses, demonstrates a significant and reproducible reduction in seizure frequency, with responder rates approaching 45 to 62% in the strongest studies, and an excellent safety profile without surgical risk.

The evidence is not yet at the level of implanted VNS, which has decades of data and the advantage of continuous, closed-loop stimulation. But for patients who decline surgery, are poor surgical candidates, or who have failed or cannot tolerate implanted VNS, tVNS represents a clinically rational option. Its accessibility, reversibility, substantially lower cost, and dual indication for comorbid mood disorders make it especially appealing in practice.

Key limitations remain: the absence of a head-to-head comparison with implanted VNS, limited long-term RCT data beyond 20 weeks, and the lack of formal NICE guidance for tVNS in epilepsy. These represent important directions for future research and health technology assessment.

Related Literature

1. Malow BA, Edwards J, Marzec M, Sagher O, Ross D, Fromes G. Vagus nerve stimulation reduces daytime sleepiness in epilepsy patients. Neurology. 2001;57:879-884.

2. Vonck K, de Herdt V, Sprengers M, Ben-Menachem E. Neurostimulation for epilepsy. Handb Clin Neurol. 2012;108:955-970.

3. Stefan H, Kreiselmeyer G, Kerling F et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia. 2012;53:e115-8.

4. DeGiorgio CM, Krahl SE. Neurostimulation for drug-resistant epilepsy. Continuum (Minneap Minn). 2013;19:743-755.

5. He W, Jing X, Wang X et al. Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: a pilot trial. Epilepsy Behav. 2013;28:343-346.

6. Aihua L, Lu S, Liping L, Xiuru W, Hua L, Yuping W. A controlled trial of transcutaneous vagus nerve stimulation for the treatment of pharmacoresistant epilepsy. Epilepsy Behav. 2014;39:105-110.

7. Rong P, Liu A, Zhang J et al. Transcutaneous vagus nerve stimulation for refractory epilepsy: a randomized controlled trial. Clin Sci (Lond). 2014

8. He W, Wang XY, Zhou L et al. Transcutaneous auricular vagus nerve stimulation for pediatric epilepsy: study protocol for a randomized controlled trial. Trials. 2015;16:371.

9. Bauer S, Baier H, Baumgartner C et al. Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02). Brain Stimul. 2016;9:356-363.

10. Oliveira TVHF, Francisco AN, Demartini Z, Stebel SL. The role of vagus nerve stimulation in refractory epilepsy. Arq Neuropsiquiatr. 2017;75:657-666.

11. Liu A, Rong P, Gong L et al. Efficacy and Safety of Treatment with Transcutaneous Vagus Nerve Stimulation in 17 Patients with Refractory Epilepsy Evaluated by Electroencephalogram, Seizure Frequency, and Quality of Life. Med Sci Monit. 2018;24:8439-8448.

12. Redgrave J, Day D, Leung H et al. Safety and tolerability of Transcutaneous Vagus Nerve stimulation in humans; a systematic review. Brain Stimul. 2018;11:1225-1238.

13. Toffa DH, Touma L, El Meskine T, Bouthillier A, Nguyen DK. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. Seizure. 2020;83:104-123.

14. Wu K, Wang Z, Zhang Y, Yao J, Zhang Z. Transcutaneous vagus nerve stimulation for the treatment of drug-resistant epilepsy: a meta-analysis and systematic review. ANZ J Surg. 2020;90:467-471.

15. Sabers A, Aumüller-Wagner S, Christensen LR et al. Feasibility of transcutaneous auricular vagus nerve stimulation in treatment of drug resistant epilepsy: A multicenter prospective study. Epilepsy Res. 2021;177:106776.

16. von Wrede R, Rings T, Schach S, Helmstaedter C, Lehnertz K. Transcutaneous auricular vagus nerve stimulation induces stabilizing modifications in large-scale functional brain networks: towards understanding the effects of taVNS in subjects with epilepsy. Sci Rep. 2021;11:7906.

17. Lampros M, Vlachos N, Zigouris A, Voulgaris S, Alexiou GA. Transcutaneous Vagus Nerve Stimulation (t-VNS) and epilepsy: A systematic review of the literature. Seizure. 2021;91:40-48.

18. von Wrede R, Surges R. Transcutaneous vagus nerve stimulation in the treatment of drug-resistant epilepsy. Auton Neurosci. 2021;235:102840.

19. Badran BW, Austelle CW. The Future Is Noninvasive: A Brief Review of the Evolution and Clinical Utility of Vagus Nerve Stimulation. Focus (Am Psychiatr Publ). 2022;20:3-7.

20. von Wrede R, Rings T, Bröhl T et al. Transcutaneous Auricular Vagus Nerve Stimulation Differently Modifies Functional Brain Networks of Subjects With Different Epilepsy Types. Front Hum Neurosci. 2022;16:867563.

21. Wang L, Wang Y, Wang Y et al. Transcutaneous auricular vagus nerve stimulators: a review of past, present, and future devices. Expert Rev Med Devices. 2022;19:43-61.

22. Yang H, Shi W, Fan J et al. Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial. Neurotherapeutics. 2023;20:870-880.

23. Gerges ANH, Williams EER, Hillier S et al. Clinical application of transcutaneous auricular vagus nerve stimulation: a scoping review. Disabil Rehabil. 2024;46:5730-5760.

24. Pan L, Wang J, Wu W, Wang Y, Zhu Y, Song Y. Transcutaneous auricular vagus nerve stimulation improves working memory in temporal lobe epilepsy: A randomized double-blind study. CNS Neurosci Ther. 2024;30:e14395.

25. Shiraishi H, Egawa K, Murakami K et al. Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy: A case series report. Brain Dev. 2024;46:49-56.

26. Xu ZYR, Fang JJ, Fan XQ et al. Effectiveness and safety of transcutaneous auricular vagus nerve stimulation for depression in patients with epilepsy. Epilepsy Behav. 2025;163:110226.

27. Makkawi S, Alsamiri GY, Halabi MH et al. Efficacy of transcutaneous vagus nerve stimulation (t-VNS) in treating drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsy Res. 2025;215:107583.

28. Premaratne S, Zoghi M, Antonic-Baker A et al. Non-invasive neuromodulation for the treatment of drug-resistant epilepsy: Protocol for a systematic review and meta-analysis investigating efficacy, safety, and optimal stimulation parameters. Syst Rev. 2025;14:214.

29. Besag FMC, Vasey MJ, Chin RFM. Recent Advances in the Management of Seizures in Children. Paediatr Drugs. 2026;28:43-68.

Review current as of April 2026. Based on evidence available up to and including early 2026.